Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer will be presenting “Examining efficacy of in vivo treatments & sharing pre-clinical data” at the 3rd Annual In Vivo Cell Engineering & Gene Editor Summit in Boston, MA.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer will be presenting “Balancing careers in Academia and Industry to Accelerate the Development of in vivo targeting genetic medicines” at the AACR Annual Meeting in Baltimore, MD.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, and Karina Krotova, Imanis Life Sciences Principal Scientist, presented “Eradication of B cell lymphoma in a mouse model through in vivo transduction of T cells with an aCD19-CAR utilizing a CD3 targeted lentiviral vector” at the AACR Annual meeting in San Diego, CA.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer attended the ACGT Annual Summit and Advisory Council Meeting in New York, NY.

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer; Mr. Scott Beck, Vyriad Chief Operating Officer; Mr. Jim Hannon, Vyriad Chief Financial Officer; Kah-Whye Peng, Chief Technical Officer; Luke Russell, Ph.D., Vyriad Director for Business Development & Strategic Alliances; and Morgan Le Naour, Business Development and Alliance Associate attended the  42^nd Annual JP Morgan Health Care Conference in San Francisco.

Sheryl Tran, Vyriad Senior Director of Quality and Compliance will be presenting at the 8^th Annual Oncolytic Virotherapy Summit in Boston, MA

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer and Luke Russell, Ph.D., Vyriad Director for Business Development & Strategic Alliances attended the 38^th Annual SITC Conference in San Diego, CA. Morgan Le Naour, Vyriad Business Development and Alliance Associate presented at the 38^th Annual SITC Conference in San Diego, CA.

Morgan Le Naour, Vyriad Business Development and Alliance Associate presented at the Cell & Gene Meeting on the Mesa in Carlsbad, CA

Morgan Le Naour, Vyriad Business Development and Alliance Associate attended and Karina Kortova, Imanis Life Sciences Senior Scientist presented at the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy in Toronto, Ontario, Canada

Luke Russell, Ph.D., Vyriad Director for Business Development & Strategic Alliances attended the Fall 2023 Longwood Healthcare Leaders Conference in Boston, Massachusetts.

Morgan Le Naour, Vyriad Business Development and Alliance Associate attended the 8^th CAR-TCR Summit in Boston, Massachusetts.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer will be attending the annual ASH meeting in San Diego, CA

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer presented: “Engineering VSV-G for targeted in vivo CAR gene delivery & oncolytic virotherapy” at the15th Annual International Oncolytic Virotherapy Conference. Kah-Whye Peng, Ph.D., Vyriad Co-Founder and Chief Technical Officer attended the 15^th Annual International Oncolytic Virotherapy Conference in Banff.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer provided a talk for the Infectious Diseases Through an Evolutionary Lens Conference.  “Targeting Virus Attachment and Entry for Biomedical Applications”.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer presented at the WMIC 2023 conference. “Radioisotopic NIS Reporter Gene Imaging to Accelerate the Development of Genetic and Regenerative Medicine” in Prague. Kah-Why Peng, Ph.D., Vyriad Chief Technical Officer, attended the WMIC 2023 conference in Prague.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer attended the ASGCT Spotlight on Immuno-Oncology Conference in Seattle, WA.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer presented: “Perspective on Engineered Oncolytic Gene Therapy” at the Genome Writers Guild in Minneapolis, MN

Dr. Stephen Russell is an invited panelist:  “Building a Biotech Business”

Luke Russell, Ph.D., Vyriad Director of Business Development and Strategic Alliances and Morgan Le Naour, Vyriad Business Development and Alliance Associate attended the InVivo Engineering of Therapeutics Cell Summit in Boston, MA.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer and Scott Beck, MBA, Vyriad Chief Operating Officer attended the 9^th Annual Immuno-Oncology Innovation Forum at the Waldorf Astoria in Chicago, IL.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer and Kah-Whye Peng, Ph.D., Vyriad Co-Founder and Chief Technical Officer attended the ASCO Annual Meeting at McCormick’s Place in Chicago, IL.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer attended the ACGT Annual Summit and Advisory Council Meeting in New York, NY.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer and Kah-Whye Peng, Ph.D., Vyriad Co-Founder and Chief Technical Officer attended the 26^th Annual ASGCT meeting in Los Angeles, CA

Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer will be attending the 2022 ESMO Immuno-Oncology Congress

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer presented “In Vivo Generation of Functional CD19 CAR-T Cells Using a Serum-Stable CD3-Targeting Lentiviral Vector” at the 65^th Annual ASH meeting in San Diego, CA. Kah-Whye Peng, Ph.D., Vyriad Co-Founder and Chief Technical Officer; Luke Russell, Ph.D., Vyriad Director for Business Development & Strategic Alliances and Morgan Le Naour, Vyriad Business Development and Alliance Associate attended the 65^th ASH meeting in San Diego, CA

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer will be attending the ASH Annual Meeting virtually.

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer.  Presentation: “Intravenous Administration of an Oncolytic Vesicular Stomatitis Virus: Clinical Experience to Date.”

Sheryl Tran, Vyriad Senior Director, Quality and Compliance.  Presentation:  Workshop A – Advancing CMC, Quality Control & Manufacturing Policies

Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer will be attending the 14^th International Oncolytic Virotherapy Conference

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, and Luke Russell, Ph.D., Vyriad Director of Alliance Management will be attending the BIO International Convention in San Diego.

Luke Russell, Ph.D., Vyriad Director of Alliance Management and Alice Bexon, M.D., Vyriad Chief Medical Officer. Poster Presentation:  Jose Lutzky, M.D., University of Miami Health System. VV1 oncolytic virus + cemiplimab + Ipilimumab in patients with melanoma or NSCLC

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, attending the ASGCT Annual Meeting virtually.

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, and Luke Russell, Ph.D., Vyriad Director of Alliance Management attended the virtual 40^th Annual JP Morgan Health Care Conference

Dr. Alice Bexon, Vyriad, Chief Medical Officer; Vino Raj, Vyriad, Medical Director; and Rebecca Thomason, Vyriad, Clinical Program Manager, will be attending the 36^th SITC meeting in Washington, DC

Dr. Kah Whye Peng was presented with the Golden Virus Award for her outstanding contribution to the field of virotherapy.

Dr. Shruthi Naik, Vyriad, Vice President, Comparative Oncology.  Poster presentation:  Safety and efficacy of neoadjuvant intravesical MV-NIS in patients with urothelial carcinoma

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Resurgence of the Oncolytic Measles Platform: Armed, Resurfaced and Precision Targeted.”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Intravenous Oncolytic Virotherapy Using Voyager-V1 (VSV-IFNb-NIS).”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Lentiviral Vectors Stealthed for In Vivo T Cell Transduction and Retargeted Via Surface Display of a CD3-Specific scFv.”

Dr. Rianna Vandergaast, Principal Scientist for Imanis Life Sciences. Presentation: “IMMUNO-COV: Measuring Protection From SARS-CoV-2.”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Entrepreneurial Growth / Oncolytic Virus.” Panel Discussion: “Entrepreneurial Snapshot / Growing Capability Company by Company”

Stephen J. Russell, M.D., Ph.D., President of ASGCT and Vyriad Chief Executive Officer presented the “Welcome Statement”.

Dr. Russell held the “Fireside Chat” with Jennifer A. Doudna, Ph.D., co-recipient of the 2020 Nobel Prize in Chemistry for the discovery of the genome-editing tool CRISPR-Cas9.

Dr. Russell chaired the following Roundtable Discussion:
“COVID-19: Vaccines to the Rescue” with Sarah Gilbert, Ph.D., University of Oxford; Larry Corey, M.D., Fred Hutchinson Cancer Research Center; Gregory Poland, M.D., Mayo Clinic; Ligia Pinto, Ph.D., Frederick National Laboratory for Cancer Research and Philip Dormitzer, M.D., Ph.D., Pfizer

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer. Presentation: “Career Paths in Industry.”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: “Engineering the Immune Response to Blaze a Trail for Oncolytic Immunotherapy.” Panel Discussion: Current Challenges in Oncolytic Virotherapy

Poster Presentations:
Ph 2 trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma

Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors

Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC) for urothelial carcinoma but ineligible for neoadjuvant cisplatin-based chemotherapy

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer. Presentation: Education Talk with Overview “Choosing the OV Platform: Considerations”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Pharmico-Dynamic Non-Invasive Monitoring Techniques”

See Speakers

Shruthi Naik, Ph.D., Vyriad Vice President of Comparative Oncology
Presentation: “Unlocking the Potential of Oncolytic Viruses to Target Cancer Cells”

Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer
Opening Remarks

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Inflaming tumors with systemic VSV therapy”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Novel Therapeutics and Diagnostics for Cancer Immunotherapy”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Systemic OV Therapy Using Voyager-V1”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Intravenous Virotherapy: Inflaming Tumors via the Blood Stream”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Antibody Targeted Viruses: The Next Generation of Oncolytics”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Voyager-V1: Systemic, Single-cycle, Trackable Oncolytic Virotherapy”

Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer
Presentation: “Oncolytic Viruses for IV Cancer Therapy”

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 37th Annual JP Morgan Healthcare Conference in San Francisco.

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus.”
Dr. Russell will also co-chair a panel session entitled: Comparing and Contrasting Virus Types.

Stephen J. Russell, M.D., Ph.D., Vyriad President and CEO, attended the 30th Annual Piper Jaffray Healthcare Conference in New York.

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Progress with Oncolytic Vesicular Stomatitis Viruses”

Stephen J. Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Presentation: “Systemic Cancer Therapy Using Oncolytic VSVs: The Voyager Platform”
Dr. Russell will participate in a panel discussion, “Explore Novel Approaches to Identify the Most Rational Combinations“

Alice Bexon, M.D., Vyriad Chief Medical Officer will attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been elected Vice-President of ASGCT. ASGCT has elected four new members to the Board of Directors, including Dr. Stephen J. Russell as new incoming vice president. Dr. Russell will serve a yearlong term as vice president before serving as ASGCT’s president-elect and, finally, president through the 2021 annual meeting. Dr. Russell will be Co-Chairing: Clinical Trials Spotlight I at the annual meeting. Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to present: Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging and Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been invited to Chair, Innate and collateral adaptive tumor immunity. Dr. Russell will also participate in Steve Russell (Once should be enough!) vs. Alan Melcher (Repeat dosing is crucial!) Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to Chair, Translation, imaging and clinical breakthroughs. Dr. Peng will be presenting: Oncolytic virus encoding IFNbeta: optimizing therapeutic index.

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 36th Annual JP Morgan Healthcare Conference in San Francisco.

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, was invited as a panel member for: How Can We Improve the Efficacy of Oncolytic Virotherapies? Dr. Russell also provided a presentation entitled “VSV-IFNb-NIS and MV-NIS: A Tale of Two Paradigms” and managed a workshop entitled “Optimizing Oncolytic Viruses: Identifying the Right Viral Platform”

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presented “Oncolytic Virotherapy: The Next Major Breakthrough in Cancer Treatment” at the 28th Annual Piper Jaffray Healthcare Conference

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, attended the annual SITC meeting

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer
Invited to present “Oncolytic Viruses: An Emerging Cornerstone for Immuno-oncology” at the Dr. Boenjamin Setiawan Distinguished Lecture Series

Stephen J Russell from Vyriad was invited to present on “Viral Therapy” at the ASCO-SITC conference on exploiting viruses for cancer therapy in combination with immune modulators.

Kah-Whye Peng, PhD, CTO of Vyriad gave a Plenary presentation entitled “Vesicular stomatitis virus (VSV) as an oncolytic agent”. Stephen J. Russell, MD, PhD, CEO & President of Vyriad gave a Plenary presentation entitled “Measles as a versatile oncolytic agent”.

Keynote Lecture: “Oncolytic Viruses: Past, Present, and Future” Stephen J. Russell, MD, PhD, CEO & President, Vyriad.